Jamie Sundsbak

Jamie Sundsbak

About

Detail

Director Accelerate
Rochester, Minnesota, United States

Timeline

work
Job
school
Education

Résumé

Jobs verified_user 0% verified
  • Mayo Clinic Platform
    Director Accelerate
    Mayo Clinic Platform
    Apr 2025 - Current (1 year 7 months)
    The director role involves overseeing various aspects of the Accelerate program, including managing resources, supporting companies, and ensuring the success of the program.
  • Mayo Clinic Platform
    Sr. Manager - Accelerate
    Mayo Clinic Platform
    Dec 2023 - Apr 2025 (1 year 5 months)
    I am privileged to serve as Sr. Manager for the Mayo Clinic Platform_Accelerate program. This 30-week initiative is dedicated to facilitating the advancement of early-stage health technology developers by providing access to the extensive resources of the Mayo Clinic Platform, thereby accelerating their journey to market.
  • Mayo Clinic
    Partner Relationship Manager - Mayo Clinic Platform Accelerate
    Mayo Clinic
    Dec 2021 - Dec 2023 (2 years 1 month)
    Mayo Clinic Platform firmly believes that health tech startups are key to sparking life-changing innovations. Which is why we developed Mayo Clinic Platform Accelerate, a 20-week program that helps early-stage health tech AI startups get market-ready.
  • Collider
    Executive Director
    Collider
    Mar 2021 - Dec 2021 (10 months)
    Collider Foundation is a 501(c)(3) organization that activates, connects, and empowers entrepreneurs in Rochester, Minnesota
  • Collider
    Interim Executive Director
    Collider
    Sep 2020 - Mar 2021 (7 months)
    Collider is a 501(c)(3) nonprofit that works to listen, connect, and empower entrepreneurs in Rochester, Minnesota. Our team works directly with entrepreneurs to understand barriers and co-create solutions.
  • Collider
    Director of Operations
    Collider
    Nov 2018 - Mar 2021 (2 years 5 months)
    The Collider Foundation is a non-profit dedicated to building an inclusive and healthy entrepreneurial ecosystem in Rochester, Minnesota by facilitating connections, education, and storytelling that surrounds and supports Rochester’s entrepreneurs.
  • Collider
    Community Manager
    Collider
    Jul 2016 - Sep 2020 (4 years 3 months)
    Collider Coworking is a hub for entrepreneurs to work, connect and learn. Located in the historic Conley-Maass building in Rochester’s Discovery Square District, Collider Core offers space perfect for a solo entrepreneur all the way up to small teams.

    Collider also aids entrepreneurs by leveraging the resources of the community to remove barriers to success.
  • Startup Digest
    Curator
    Startup Digest
    Mar 2016 - Jul 2017 (1 year 5 months)
    Responsible for the curation of weekly entrepreneurial events in Rochester, Minnesota area.
  • Mayo Clinic
    Sr. Research Program Coodinator
    Mayo Clinic
    Nov 2014 - Jul 2016 (1 year 9 months)
    Operations Manager of Mayo's Surgical Device Innovation Accelerator.
  • C
    Co-Founder
    Colidr Social Innovation Lab
    Nov 2013 - Aug 2014 (10 months)
    - Co-created Rochester’s first social innovation laboratory
    - Focused on helping people with great ideas overcome fear, uncertainty, and doubt and execute on their ideas
    - Created a three month “acceleration curriculum” using a variant of the “Business Model Canvas” and the “Lean Launchpad for Startups”
    - Took on an advisory role in August of 2014 in order to focus on BioAM
  • B
    Founder
    BioAM LLC
    Mar 2013 - Jul 2016 (3 years 5 months)
    - Created an organization that promotes BioBusiness in the Rochester area
    - Organized 200 events in Rochester to promote “random collisions” of people with great ideas
    - Designed and maintain BioAM website, social media, and weekly newsletter.
    - Self funded trips to entrepreneurial startup communities across the United States to better understand what makes these communities successful
  • R
    Founder and Chief Architect
    RochesterCommonscom
    May 2012 - May 2013 (1 year 1 month)
    - Designed and maintain a hyperlocal social network dedicated to improving life in Rochester, MN
    - Responsible for RochesterCommons social media (Twitter and Facebook accounts) as well as blog
    - Site abandoned to focus on BioAM
  • Mayo Clinic
    Sr. Research Technologist/Project Manager
    Mayo Clinic
    Aug 2008 - Jul 2016 (8 years)
    - Responsible for laboratory operations for a center that performs genotyping services for researchers worldwide
    - Designed and created a Genetic Laboratory Information Management (GLIMS) system to track genetic information and aid sample collection
    - Responsible for budget, financial tracking, and effort certification of a large research program
    - Co-author of 11 publications and numerous grants and abstracts
  • Mayo Clinic
    Clinical Laboratory Technician
    Mayo Clinic
    Jul 2006 - Sep 2008 (2 years 3 months)
    - Performed molecular genetic testing for patients worldwide
    - Performed QC/QA testing and troubleshooting of assays
    - Liquid handling and robotic automation training
  • L
    Founder and Chief Architect Life Science Nexus
    Life Science Nexus
    Jun 2003 - Jun 2006 (3 years 1 month)
    - Two person startup focused on creating a social network for scientists
    - Developed and launched beta version of the product
    - Site was developed using Ruby on Rails with a MySQL database and running on local Apache server
    - Startup was discontinued when both founders were offered other positions
  • University of Utah
    Sr. Laboratory Specialist
    University of Utah
    Jun 2001 - Jun 2006 (5 years 1 month)
    - Research focused on understanding the pathogenesis of Uropathogenic E.coli (UPEC) during human bladder infections
    - Responsible for a 10 person laboratory team which included day to day direction and 360 evaluation
    - Developed an assay to test candidate drugs in a human bladder cell culture system
    - Worked with a mouse model of the disease to better understand pathogenesis and drug candidate effects
  • Mayo Clinic
    Clinical Laboratory Technician
    Mayo Clinic
    Mar 1999 - Jun 2001 (2 years 4 months)
    - Performed molecular genetic testing for patients worldwide
    - Performed QC/QA testing and troubleshooting of assays
    - Worked as part of a team charged with decreasing assay turnaround time and error rate
    - Focused on bringing new innovations into the laboratory
  • USDA
    Undergraduate Research Lab Technician
    USDA
    Jun 1994 - Mar 1999 (4 years 10 months)
    - Focus of undergraduate thesis research was to design PCR based diagnostic tests for fungal pathogens
    - Used basic molecular biology techniques and equipment
    - Trained other undergraduate students and helped to manage the laboratory
Education verified_user 0% verified
  • North Dakota State University
    BS, Biotechnology
    North Dakota State University
    Jan 1994 - Jan 1998 (4 years 1 month)
  • University of Utah
    Business Administration, Management and Operations
    University of Utah
    Various management training classes
    Accounting and budgeting classes
    Did not finish MBA due to family issues
Awards verified_user 0% verified
  • R
    RAVE Warrior Award
    Rochester Area Economic Development Inc
    Recipient of the the RAVE Warrior Award for promoting entrepreneurship in Rochester.
  • T
    Twin Cities Business 100 - 2025
    Twin Cities Business Magazine
    Selected as one of top 100 leaders in Minnesota for 2025. The TCB 100 is the list of all lists, the essential guide to people in and around Minnesota business likely to make news and drive change in the year ahead.
Publications verified_user 0% verified
  • S
    Successful disease-specific induced pluripotent stem cell generation from patients with kidney transplantation.
    Stem Cell Research and Therepeutics Dec
    Abstract
    INTRODUCTION:
    End-stage renal disease (ESRD) is a major public health problem. Although kidney transplantation is a viable therapeutic option, this therapy is associated with significant limitations, including a shortage of donor organs. Induced pluripotent stem (iPS) cell technology, which allows derivation of patient-specific pluripotent stem cells, could provide a possible alternative modality for kidney replacement therapy for patients with ESRD.
    METHODS:
    The feasibility of iPS cell generation from patients with a history of ESRD was investigated using lentiviral vectors expressing pluripotency-associated factors.
    RESULTS:
    In the present article we report, for the first time, generation of iPS cell
  • P
    Integrin-mediated host cell invasion by type 1-piliated uropathogenic Escherichia coli.
    PLoS Pathogens Jul
    Uropathogenic Escherichia coli (UPEC), the primary causative agent of urinary tract infections, typically express filamentous adhesive organelles called type 1 pili that mediate both bacterial attachment to and invasion of bladder urothelial cells. Several host proteins have previously been identified as receptors for type 1 pili, but none have been conclusively shown to promote UPEC entry into host bladder cells. Using overlay assays with FimH, the purified type 1 pilus adhesin, and mass spectroscopy, we have identified beta1 and alpha3 integrins as key host receptors for UPEC. FimH recognizes N-linked oligosaccharides on these receptors, which are expressed throughout the urothelium. In a bladder cell culture system, beta1 and alpha3 inte
  • P
    Somatotroph pituitary adenoma with acromegaly and autosomal dominant polycystic kidney disease: SSTR5 polymorphism and P
    Pituitary Jul
    A 39-year-old woman with autosomal dominant polycystic kidney disease (ADPKD) presented with acromegaly and a pituitary macroadenoma. There was a family history of this renal disorder. She had undergone surgery for pituitary adenoma 6 years prior. Physical examination disclosed bitemporal hemianopsia and elevation of both basal growth hormone (GH) 106 ng/mL (normal 0-5) and insulin-like growth factor (IGF-1) 811 ng/mL (normal 48-255) blood levels. A magnetic resonance imaging scan disclosed a 3.0 cm sellar and suprasellar mass with both optic chiasm compression and left cavernous sinus invasion. Pathologic, cytogenetic, molecular and in silico analysis was undertaken. Histologic, immunohistochemical and ultrastructural studies of the lesion
  • C
    Extended follow-up of unruptured intracranial aneurysms detected by presymptomatic screening in patients with autosomal
    Clinical Journal of the American Society of Nephrology Jun
    SummaryBackground and objectives Autosomal dominant polycystic kidney disease (ADPKD) patients have an increased risk for intracranial aneurysms (IAs). The importance of screening for unruptured IAs (UIAs) depends on their risks for growth and rupture. Design, setting, participants, & measurements ADPKD patients with UIAs found by presymptomatic screening with magnetic resonance angiography (MRA) during 1989 to 2009 were followed initially at 6 months and annually, and less frequently after demonstration of stability. Results Forty-five saccular aneurysms were detected in 38 patients from 36 families. Most were small (median diameter 3.5 mm) and in the anterior circulation (84%). Median age at diagnosis was 49 years. During cumulative imagi
  • J
    Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing.
    Journal of the American Society of Nephrology May
    Mutations in two large multi-exon genes, PKD1 and PKD2, cause autosomal dominant polycystic kidney disease (ADPKD). The duplication of PKD1 exons 1-32 as six pseudogenes on chromosome 16, the high level of allelic heterogeneity, and the cost of Sanger sequencing complicate mutation analysis, which can aid diagnostics of ADPKD. We developed and validated a strategy to analyze both the PKD1 and PKD2 genes using next-generation sequencing by pooling long-range PCR amplicons and multiplexing bar-coded libraries. We used this approach to characterize a cohort of 230 patients with ADPKD. This process detected definitely and likely pathogenic variants in 115 (63%) of 183 patients with typical ADPKD. In addition, we identified atypical mutations, a
  • H
    B9D1 is revealed as a novel Meckel syndrome (MKS) gene by targeted exon-enriched next-generation sequencing and deletion
    Human Molecular Genetics Jun
    Meckel syndrome (MKS) is an embryonic lethal, autosomal recessive disorder characterized by polycystic kidney disease, central nervous system defects, polydactyly and liver fibrosis. This disorder is thought to be associated with defects in primary cilia; therefore, it is classed as a ciliopathy. To date, six genes have been commonly associated with MKS (MKS1, TMEM67, TMEM216, CEP290, CC2D2A and RPGRIP1L). However, mutation screening of these genes revealed two mutated alleles in only just over half of our MKS cohort (46 families), suggesting an even greater level of genetic heterogeneity. To explore the full genetic complexity of MKS, we performed exon-enriched next-generation sequencing of 31 ciliopathy genes in 12 MKS pedigrees using Rai
  • C
    Actin-gated intracellular growth and resurgence of uropathogenic Escherichia coli.
    Cell Microbiology Apr
    Strains of uropathogenic Escherichia coli (UPEC) can invade terminally differentiated superficial bladder epithelial cells and subsequently multiply, forming large biofilm-like inclusions referred to as pods. In contrast, within immature bladder cells UPEC enter a more quiescent state and often fail to replicate appreciably. As immature bladder epithelial cells undergo terminal differentiation the actin cytoskeleton is radically diminished, a phenomenon that we reasoned could influence the intracellular fate of UPEC. Here we show that UPEC within undifferentiated bladder cells is trafficked into acidic compartments having key features of late endosomes and lysosomes. These UPEC-containing vacuoles are often enmeshed within a network of acti
This is a community-created genome.